Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors
Rubinfeld expected to assist with FDA approval process for autologous cultured skin substitute, PermaDerm(TM)
27-Aug-2010 -
Regenicin, Inc., a clinical-stage biotechnology company, announced that Dr. Joseph Rubinfeld, one of the four original founders of Amgen, Inc., has agreed to join the company's board of directors. Dr. Rubinfeld will be instrumental to assisting the compan's commercialization efforts of ...
Amgen
biotechnology
bleomycin
+5